Latest Outlook Therapeutics News & Updates

See the latest news and media coverage for Outlook Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Outlook Therapeutics

Biopharmaceutical company developing and commercializing retinal disease therapies

outlooktherapeutics.com

Headquarters: Iselin, United States
Founded year: 2011
Company type: Public company
Number of employees: 10–80
Industry: Pharmaceuticals

Last updated Today

Latest news about Outlook Therapeutics

In short: Outlook Therapeutics advanced LYTENAVA's wet AMD launch after FDA approval, priced it at $485/vial, and targeted a US launch by end-2026.

Company announcements

October 6 Outlook Therapeutics

Outlook Therapeutics highlights new CFO appointment

Kevin Lundquist's role discussed in virtual investor chat, focusing on the company’s next strategic chapter and implications for ophthalmology operations.

October 1 Outlook Therapeutics

Outlook Therapeutics submits CMS application for J-code

The company seeks a permanent HCPCS Level II code for LYTENAVA to support reimbursement ahead of its planned U.S. commercial launch in late 2026.

September 9 Outlook Therapeutics

Outlook Therapeutics receives FDA approval for LYTENAVA treatment

The medication serves as the exclusive ophthalmic bevacizumab formulation designed for managing neovascular eye conditions.

September 2 Outlook Therapeutics

Outlook Therapeutics insider trades reported by Kevin Lundquist

Form 4 filed on September 2, 2026, discloses changes in beneficial ownership for Kevin Michael Lundquist regarding the company's securities.

Media coverage

September 19 The Globe and Mail

Outlook Therapeutics Sets U.S. Price for LYTENAVA

Outlook Therapeutics ( (OTLK) ) has provided an announcement.

September 10 Yahoo Finance

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal ...

August 28 The Globe and Mail

Outlook Therapeutics Announces CFO Transition and Board Change

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

August 25 IT BOLTWISE

Outlook Therapeutics: GMS Ventures stock surges – LYTENAVA moves into focus

Outlook Therapeutics stabilizes after $55 million capital increase. GMS Ventures surges by 16.4%, while analysts cite $4.00 price targets. LYTENAVA draws closer.

Never miss news about Outlook Therapeutics

Track Outlook Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Outlook Therapeutics competitors & trending companies

Browse news for competitors to Outlook Therapeutics and other trending companies.